SUCCINYLCHOLINE CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Succinylcholine Chloride patents expire, and what generic alternatives are available?
Succinylcholine Chloride is a drug marketed by Accord Hlthcare, Amneal, Amphastar Pharms Inc, Amring Pharms, Aspiro, Be Pharms, Breckenridge, Deva Holding As, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Indoco, Intl Medication, Mankind Pharma, Meitheal, Micro Labs, Nexus, Nivagen Pharms Inc, Organon Usa Inc, Sagent Pharms Inc, Somerset Theraps Llc, and Zydus Pharms. and is included in twenty-six NDAs.
The generic ingredient in SUCCINYLCHOLINE CHLORIDE is succinylcholine chloride. There are six drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the succinylcholine chloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Succinylcholine Chloride
A generic version of SUCCINYLCHOLINE CHLORIDE was approved as succinylcholine chloride by ZYDUS PHARMS on May 4th, 2018.
Summary for SUCCINYLCHOLINE CHLORIDE
US Patents: | 0 |
Applicants: | 24 |
NDAs: | 26 |
Finished Product Suppliers / Packagers: | 26 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Clinical Trials: | 2 |
Patent Applications: | 1,270 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SUCCINYLCHOLINE CHLORIDE |
What excipients (inactive ingredients) are in SUCCINYLCHOLINE CHLORIDE? | SUCCINYLCHOLINE CHLORIDE excipients list |
DailyMed Link: | SUCCINYLCHOLINE CHLORIDE at DailyMed |
Recent Clinical Trials for SUCCINYLCHOLINE CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Rutgers, The State University of New Jersey | N/A |
Avera Pharmaceuticals | Phase 1/Phase 2 |
Pharmacology for SUCCINYLCHOLINE CHLORIDE
Drug Class | Depolarizing Neuromuscular Blocker |
Physiological Effect | Neuromuscular Depolarizing Blockade |